Interleukin-6
COVID-19
Interleukin
Lymphocytes
Monoclonal antibodies
SARS-CoV-2
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
28
02
2023
accepted:
18
04
2023
medline:
2
11
2023
pubmed:
25
4
2023
entrez:
25
4
2023
Statut:
ppublish
Résumé
In a convenience sample of 93 patients treated with monoclonal antibodies (moAbs) against SARS-CoV-2, the interleukin-6
Identifiants
pubmed: 37097384
doi: 10.1007/s10238-023-01081-6
pii: 10.1007/s10238-023-01081-6
pmc: PMC10127195
doi:
Substances chimiques
Interleukin-6
0
Antibodies, Monoclonal
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3681-3687Investigateurs
Francesca Serapide
(F)
Bruno Tassone
(B)
Paolo Fusco
(P)
Chiara Davoli
(C)
Valentina La Gamba
(V)
Helen Linda Morrone
(HL)
Lavinia Berardelli
(L)
Maria Teresa Tassone
(MT)
Riccardo Serraino
(R)
Chiara Costa
(C)
Daniela Patrizia Foti
(DP)
Federico Longhini
(F)
Andrea Bruni
(A)
Eugenio Garofalo
(E)
Eugenio Biamonte
(E)
Domenico Laganà
(D)
Maria Petullà
(M)
Bernardo Bertucci
(B)
Giorgio Settimo Barreca
(GS)
Aida Giancotti
(A)
Luigia Gallo
(L)
Angelo Lamberti
(A)
Maria Carla Liberto
(MC)
Nadia Marascio
(N)
Adele Emanuela De Francesco
(AE)
Informations de copyright
© 2023. The Author(s).
Références
Maier HE, Kuan G, Saborio S, et al. Clinical spectrum of SARS-CoV-2 infection and protection from symptomatic re-infection. Clin Infect Dis. 2021. https://doi.org/10.1093/cid/ciab717 .
doi: 10.1093/cid/ciab717
pubmed: 32975293
pmcid: 8499752
Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. J Intensive Care. 2020;8:36. https://doi.org/10.1186/s40560-020-00453-4 .
doi: 10.1186/s40560-020-00453-4
pubmed: 32483488
pmcid: 7245646
Huang W, Berube J, McNamara M, et al. Lymphocyte subset counts in COVID-19 patients: a meta-analysis. Cytom A. 2020;97:772–6. https://doi.org/10.1002/cyto.a.24172 .
doi: 10.1002/cyto.a.24172
Izcovich A, Ragusa MA, Tortosa F, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: a systematic review. PLoS ONE. 2020;15:e0241955. https://doi.org/10.1371/journal.pone.0241955 .
doi: 10.1371/journal.pone.0241955
pubmed: 33201896
pmcid: 7671522
Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95:834–47. https://doi.org/10.1002/ajh.25829 .
doi: 10.1002/ajh.25829
pubmed: 32282949
pmcid: 7262337
Velavan TP, Meyer CG. Mild versus severe COVID-19: laboratory markers. Int J Infect Dis. 2020;95:304–7. https://doi.org/10.1016/j.ijid.2020.04.061 .
doi: 10.1016/j.ijid.2020.04.061
pubmed: 32344011
pmcid: 7194601
Illg Z, Muller G, Mueller M, Nippert J, Allen B. Analysis of absolute lymphocyte count in patients with COVID-19. Am J Emerg Med. 2021;46:16–9. https://doi.org/10.1016/j.ajem.2021.02.054 .
doi: 10.1016/j.ajem.2021.02.054
pubmed: 33706251
pmcid: 7923864
Biamonte F, Botta C, Mazzitelli M, et al. Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility. J Transl Med. 2021;19:79. https://doi.org/10.1186/s12967-021-02744-2 .
doi: 10.1186/s12967-021-02744-2
pubmed: 33596963
pmcid: 7887565
Galvan-Roman JM, Rodriguez-Garcia SC, Roy-Vallejo E, et al. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: an observational study. J Allergy Clin Immunol. 2021;147:72-80 e78. https://doi.org/10.1016/j.jaci.2020.09.018 .
doi: 10.1016/j.jaci.2020.09.018
pubmed: 33010257
Herold T, Jurinovic V, Arnreich C, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol. 2020;146:128-136 e124. https://doi.org/10.1016/j.jaci.2020.05.008 .
doi: 10.1016/j.jaci.2020.05.008
pubmed: 32425269
pmcid: 7233239
Van Singer M, Brahier T, Ngai M, et al. COVID-19 risk stratification algorithms based on sTREM-1 and IL-6 in emergency department. J Allergy Clin Immunol. 2021;147:99-106 e104. https://doi.org/10.1016/j.jaci.2020.10.001 .
doi: 10.1016/j.jaci.2020.10.001
pubmed: 33045281
Gorham J, Moreau A, Corazza F, et al. Interleukine-6 in critically ill COVID-19 patients: a retrospective analysis. PLoS ONE. 2020;15:e0244628. https://doi.org/10.1371/journal.pone.0244628 .
doi: 10.1371/journal.pone.0244628
pubmed: 33382773
pmcid: 7774924
Trecarichi EM, Mazzitelli M, Serapide F, et al. Clinical characteristics and predictors of mortality associated with COVID-19 in elderly patients from a long-term care facility. Sci Rep. 2020;10:20834. https://doi.org/10.1038/s41598-020-77641-7 .
doi: 10.1038/s41598-020-77641-7
pubmed: 33257703
pmcid: 7705720
Yang B, Chang X, Huang J, et al. The role of IL-6/lymphocyte ratio in the peripheral blood of severe patients with COVID-19. Int Immunopharmacol. 2021;97:107569. https://doi.org/10.1016/j.intimp.2021.107569 .
doi: 10.1016/j.intimp.2021.107569
pubmed: 33933851
pmcid: 7953449
In Coronavirus Disease 2019 (COVID-19) Treatment Guidelines: Bethesda (MD), 2021.
Masotti L, Grifoni E, Pelagalli G, et al. Prognostic role of Interleukin-6/lymphocytes ratio in SARS-CoV2 related pneumonia. Int Immunopharmacol. 2022;103:108435. https://doi.org/10.1016/j.intimp.2021.108435 .
doi: 10.1016/j.intimp.2021.108435
pubmed: 34920336
World Medical A. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–4. https://doi.org/10.1001/jama.2013.281053 .
doi: 10.1001/jama.2013.281053
Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCR: visualizing classifier performance in R. Bioinformatics. 2005;21:3940–1. https://doi.org/10.1093/bioinformatics/bti623 .
doi: 10.1093/bioinformatics/bti623
pubmed: 16096348
Al Bander Z, Nitert MD, Mousa A, Naderpoor N. The Gut microbiota and inflammation: an overview. Int J Environ Res Public Health. 2020. https://doi.org/10.3390/ijerph17207618 .
doi: 10.3390/ijerph17207618
pubmed: 33086688
pmcid: 7589951
Oran DP, Topol EJ. Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review. Ann Intern Med. 2020;173:362–7. https://doi.org/10.7326/M20-3012 .
doi: 10.7326/M20-3012
pubmed: 32491919
Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 omicron and delta variants. JAMA. 2022;327:639–51. https://doi.org/10.1001/jama.2022.0470 .
doi: 10.1001/jama.2022.0470
pubmed: 35060999
pmcid: 8848203
Calderon-Parra J, Munez-Rubio E, Fernandez-Cruz A, et al. Incidence, clinical presentation, relapses and outcome of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection in patients treated with anti-CD20 monoclonal antibodies. Clin Infect Dis. 2022;74:1786–94. https://doi.org/10.1093/cid/ciab700 .
doi: 10.1093/cid/ciab700
pubmed: 34383032
Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus etesevimab in mild or moderate Covid-19. N Engl J Med. 2021;385:1382–92. https://doi.org/10.1056/NEJMoa2102685 .
doi: 10.1056/NEJMoa2102685
pubmed: 34260849
Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021;384:238–51. https://doi.org/10.1056/NEJMoa2035002 .
doi: 10.1056/NEJMoa2035002
pubmed: 33332778
Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385:1941–50. https://doi.org/10.1056/NEJMoa2107934 .
doi: 10.1056/NEJMoa2107934
pubmed: 34706189
Montgomery H, Hobbs FDR, Padilla F, et al. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2022. https://doi.org/10.1016/S2213-2600(22)00180-1 .
doi: 10.1016/S2213-2600(22)00180-1
pubmed: 36521509
pmcid: 9779778
Chen Q, Wang WC, Bruce R, et al. Central role of IL-6 receptor signal-transducing chain gp130 in activation of L-selectin adhesion by fever-range thermal stress. Immunity. 2004;20:59–70. https://doi.org/10.1016/s1074-7613(03)00358-3 .
doi: 10.1016/s1074-7613(03)00358-3
pubmed: 14738765
Majidpoor J, Mortezaee K. Interleukin-6 in SARS-CoV-2 induced disease: interactions and therapeutic applications. Biomed Pharmacother. 2022;145:112419. https://doi.org/10.1016/j.biopha.2021.112419 .
doi: 10.1016/j.biopha.2021.112419
pubmed: 34781146
Evans SS, Repasky EA, Fisher DT. Fever and the thermal regulation of immunity: the immune system feels the heat. Nat Rev Immunol. 2015;15:335–49. https://doi.org/10.1038/nri3843 .
doi: 10.1038/nri3843
pubmed: 25976513
pmcid: 4786079
Cohen MS. Early treatment to prevent progression of SARS-CoV-2 infection. Lancet Respir Med. 2022. https://doi.org/10.1016/S2213-2600(22)00213-2 .
doi: 10.1016/S2213-2600(22)00213-2
pubmed: 35688163
pmcid: 9173720
Scaglione V, Rotundo S, Marascio N, et al. Lessons learned and implications of early therapies for coronavirus disease in a territorial service centre in the Calabria region: a retrospective study. BMC Infect Dis. 2022;22:793. https://doi.org/10.1186/s12879-022-07774-9 .
doi: 10.1186/s12879-022-07774-9
pubmed: 36266619
pmcid: 9583059
D’Abramo A, Vita S, Nicastri E. The unmet need for COVID-19 treatment in immunocompromised patients. BMC Infect Dis. 2022;22:930. https://doi.org/10.1186/s12879-022-07918-x .
doi: 10.1186/s12879-022-07918-x
pubmed: 36503419
Scherer EM, Babiker A, Adelman MW, et al. SARS-CoV-2 evolution and immune escape in immunocompromised patients. N Engl J Med. 2022. https://doi.org/10.1056/NEJMc2202861 .
doi: 10.1056/NEJMc2202861
pubmed: 35675197
pmcid: 9202319
ACTIV-3–Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. Lancet Respir Med 2022;10:972–984. https://doi.org/10.1016/S2213-2600(22)00215-6
Group A-TBS, Lundgren JD, Grund B, et al. Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels: A Randomized Controlled Trial. Ann Intern Med 2022;175:234–243. https://doi.org/10.7326/M21-3507
Riley RD, Cole TJ, Deeks J, et al. On the 12th day of Christmas, a statistician sent to me. BMJ. 2022;379:e072883. https://doi.org/10.1136/bmj-2022-072883 .
doi: 10.1136/bmj-2022-072883
pubmed: 36593578
pmcid: 9844255
Solimando AG, Susca N, Borrelli P, et al. Short-term variations in Neutrophil-to-Lymphocyte and Urea-to-Creatinine ratios anticipate intensive care unit admission of COVID-19 patients in the emergency department. Front Med. 2020;7:625176. https://doi.org/10.3389/fmed.2020.625176 .
doi: 10.3389/fmed.2020.625176
Remy KE, Mazer M, Striker DA, et al. Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections. JCI Insight. 2020. https://doi.org/10.1172/jci.insight.140329 .
doi: 10.1172/jci.insight.140329
pubmed: 32687484
pmcid: 7526441
Liu BM, Hill HR. Role of host immune and inflammatory responses in COVID-19 cases with underlying primary immunodeficiency: a review. J Interferon Cytokine Res. 2020;40:549–54. https://doi.org/10.1089/jir.2020.0210 .
doi: 10.1089/jir.2020.0210
pubmed: 33337932
pmcid: 7757688
Furlan A, Forner G, Cipriani L, et al. COVID-19 in B cell-depleted patients after rituximab: a diagnostic and therapeutic challenge. Front Immunol. 2021;12:763412. https://doi.org/10.3389/fimmu.2021.763412 .
doi: 10.3389/fimmu.2021.763412
pubmed: 34804051
pmcid: 8595333